Clinical outcomes associated with pharmacist involvement in patients with dyslipidemia

被引:6
作者
Cross, LB
Franks, AS
机构
[1] Univ Tennessee, Hlth Sci Ctr, Dept Pharm, Coll Pharm,St Francis Family Practice Ctr, Memphis, TN 38119 USA
[2] Univ Tennessee, Hlth Sci Ctr, Dept Family Med, Coll Med,St Francis Family Practice Ctr, Memphis, TN 38119 USA
关键词
D O I
10.2165/00115677-200513010-00004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The burden of cardiovascular disease in America continues to be the leading cause of death and costs significantly more to treat ($US298.2 billion in 2002) than any other disease in the US healthcare system. Incontrovertible evidence links elevated levels of total and low-density lipoprotein-cholesterol and reduced levels of high-density lipoprotein-cholesterol with an increased risk for coronary heart disease. The subsequent treatment of hyperlipidemia has been shown to dramatically decrease morbidity and mortality related to cardiovascular disease. Research continues to show that many candidates for lipid-lowering therapy are not offered therapy and many never attain recommended National Cholesterol Education Program (NCEP) guideline goals. Increased pharmacist involvement in the treatment of patients with hyperlipidemia may represent one way to help bridge the treatment gap that exists in these high-risk patients. Limited evidence has shown that lipid values, NCEP goal attainment, and medication compliance improve when a pharmacist contributes to patient care in dyslipidemia. However, larger randomized controlled studies need to be performed to confirm the results of previous smaller retrospective trials.
引用
收藏
页码:31 / 42
页数:12
相关论文
共 50 条
[1]   Use and monitoring of "statin" lipid-lowering drugs compared with guidelines [J].
Abookire, SA ;
Karson, AS ;
Fiskio, J ;
Bates, DW .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (01) :53-58
[2]  
*AM HEART ASS, 2002, HEART STROKE STAT UP
[3]   Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J].
Athyros, VG ;
Papageorgiou, AA ;
Mercouris, BR ;
Athyrou, VV ;
Symeonidis, AN ;
Basayannis, EO ;
Demitriadis, DS ;
Kontopoulos, AG .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) :220-228
[4]  
Bluml B M, 2000, J Am Pharm Assoc (Wash), V40, P157
[5]   Effect of a clinical pharmacist-managed lipid clinic on achieving national cholesterol education program low-density lipoprotein goals [J].
Bozovich, M ;
Rubino, CM ;
Edmunds, J .
PHARMACOTHERAPY, 2000, 20 (11) :1375-1383
[6]   REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].
BROWN, G ;
ALBERS, JJ ;
FISHER, LD ;
SCHAEFER, SM ;
LIN, JT ;
KAPLAN, C ;
ZHAO, XQ ;
BISSON, BD ;
FITZPATRICK, VF ;
DODGE, HT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298
[7]   EFFECT OF PARTIAL ILEAL BYPASS-SURGERY ON MORTALITY AND MORBIDITY FROM CORONARY HEART-DISEASE IN PATIENTS WITH HYPERCHOLESTEROLEMIA - REPORT OF THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH) [J].
BUCHWALD, H ;
VARCO, RL ;
MATTS, JP ;
LONG, JM ;
FITCH, LL ;
CAMPBELL, GS ;
PEARCE, MB ;
YELLIN, AE ;
EDMISTON, WA ;
SMINK, RD ;
SAWIN, HS ;
CAMPOS, CT ;
HANSEN, BJ ;
TUNA, N ;
KARNEGIS, JN ;
SANMARCO, ME ;
AMPLATZ, K ;
CASTANEDAZUNIGA, WR ;
HUNTER, DW ;
BISSETT, JK ;
WEBER, FJ ;
STEVENSON, JW ;
LEON, AS ;
CHALMERS, TC .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :946-955
[8]   Pharmacist-coordinated program to improve use of pharmacotherapies for reducing risk of coronary artery disease in low-income adults [J].
Carson, JJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (22) :2319-2324
[9]   INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY [J].
CASTELLI, WP ;
GARRISON, RJ ;
WILSON, PWF ;
ABBOTT, RD ;
KALOUSDIAN, S ;
KANNEL, WB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20) :2835-2838
[10]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497